Dantrolene: Difference between revisions
ClaireLewis (talk | contribs) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 44: | Line 44: | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Dantrolene]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
Latest revision as of 21:57, 20 March 2026
Administration
- Type: Skeletal muscle relaxant
- Dosage Forms:
- Routes of Administration: IV, oral
- Common Trade Names: Dantrium
Adult Dosing
Neuroleptic malignant syndrome
- 0.25-2mg/kg IV q6-12hr
- Max dose 10mg/kg/day
Pediatric Dosing
- Same as above
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: contraindicated in acute hepatitis or active cirrhosis
Contraindications
- Allergy to class/drug
- Acute hepatitis or active cirrhosis
Adverse Reactions
Serious
- Hepatotoxicity
- GI bleed
- Aplastic anemia, leukopenia, thrombocytopenia, small lymphocytic lymphoma
- Muscle weakness, dysphagia, reduced vital capacity, dyspnea
Common
- Flushing
- Somnolence, fatigue, malaise
- Nausea, diarrhea
Pharmacology
- Half-life: 10.8h
- Metabolism: Hepatic
- Excretion:
Mechanism of Action
- Interferes with release of calcium ions from sarcoplasmic reticulum in skeletal muscle, which results in dissociation of the excitation-contraction coupling
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.